Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Zoetis Stock: Why 12 Pipeline Blockbusters Could Support a 40% Upside - TIKR.com

AI-generated analysis

📉 ZTS stock trades at $125.93, down nearly 29% from its 52-week high of $177.00.

💰 Q4 adjusted EPS beat estimates at $1.48 versus a consensus of $1.40.

🤝 Zoetis acquired Neogen's genomics business for $160 million on March 2 to expand precision capabilities.

💊 Simparica franchise generated $1.5 billion in 2025 revenue with 12% operational growth.

🚀 Simparica Trio crossed $1 billion in U.S. annual sales for the first time.

⚠️ Merck's Numelvi received FDA approval on February 25, intensifying dermatology competition.

🔬 CYTOPOINT long-acting approval is expected late 2026 to offset portfolio pressure.

🌍 Lenivia is scheduled to launch in EU and Canada in the first half of 2026.

📈 Revenue projected to grow from $9.5B in 2025 to $9.9B in 2026.

💹 Normalized EPS expected to accelerate 9.6% to $7.0 in 2026.

🛡️ Livestock segment delivered 8% organic operational growth in 2025.

📊 EBITDA margins held steady at 44.8% in 2025 despite market headwinds.

👥 Wall Street consensus includes 7 buys, 4 outperforms, and 9 holds.

🎯 Mean analyst price target is $151.0, implying 19.9% upside from current price.

📉 Librela U.S. sales declined 32% in Q4, posing a significant near-term risk.

🔮 TIKR model targets $178.4 by end of 2030 for a 41.7% total return.

🗣️ CEO Kristin Peck attributes recent softness to price sensitivity and tighter household budgets.

📉 CFO Wetteny Joseph highlighted a disconnect between business performance and current valuation.

Bullish Signals
  • Zoetis beat Q4 revenue estimates by $27 million while delivering adjusted EPS of $1.48 against a $1.40 estimate.
  • The Simparica franchise achieved $1.5 billion in 2025 revenue with 12% operational growth and crossed the $1 billion U.S. sales mark.
  • Livestock segment delivered strong 8% organic operational growth in 2025, diversifying revenue streams beyond companion animals.
  • The company maintains robust structural profitability with EBITDA margins holding at 44.8% despite competitive pressures.
  • A diverse pipeline of 12 potential blockbusters, including CYTOPOINT and Lenivia, extends the competitive lead beyond current franchise challenges.
  • Management views the current $125.93 price as undervalued relative to a TIKR model target of $178.4 by 2030.
  • Analyst consensus includes 7 buys and 4 outperforms with a mean price target of $151.0 implying nearly 20% upside.
Risk Factors
  • Simparica, dermatology, and OA pain franchises came in lighter than expected due to greater price sensitivity and tighter household budgets.
  • Merck's Numelvi received FDA approval on February 25, intensifying competition in the dermatology segment.
  • Librela U.S. sales declined 32% in Q4, representing the single biggest threat if weakness spreads to the broader OA pain franchise.
  • The low-end analyst price target of $130 reflects concerns about sustained Librela decline and fatigue around U.S. companion animal softness.
Full Analysis
Zoetis (ZTS) shares are trading at $125.93, nearly 29% below their 52-week high, despite the company beating Q4 revenue estimates by $27 million and acquiring Neogen's genomics business for $160 million on March 2. While certain franchises like Simparica, dermatology, and OA pain faced lighter-than-expected performance due to price sensitivity and new FDA-approved competition from Merck's Numelvi, Zoetis still delivered Q4 adjusted EPS of $1.48 against a $1.40 estimate. The company is building a robust pipeline with 12 potential blockbusters in development, including CYTOPOINT long-acting approval expected late 2026 and Lenivia launching in EU and Canada in the first half of 2026. The Neogen acquisition reinforces Zoetis's precision animal health capabilities, aligning with analyst consensus for 4.7% revenue growth in 2026 as the business stabilizes following a turbulent year. Fundamentally, revenue is projected to grow from $9.5 billion in 2025 to $9.9 billion in 2026, with normalized EPS accelerating 9.6% to $7.0. Zoetis generated $4.2 billion in EBITDA in 2025 at 44.8% margins, maintaining structural profitability despite competitive pressures. Management views the current valuation as disconnected from these fundamentals, citing a disconnect between performance and market price. Analysts maintain a mean price target of $151.0, implying 19.9% upside, though targets range from $130 to $190 depending on the trajectory of Librela's decline and future approvals. A TIKR valuation model projects a target of $178.4 by December 31, 2030, suggesting a 41.7% total return and 7.5% annual IRR. The primary risk remains the potential spread of Librela's Q4 decline to the broader OA pain franchise.